Current best practices and rationalistic perspectives in causation-based prevention, early detection and multidisciplinary treatment of breast and gastric cancer

Gastric & Breast Cancer e-journal
DOI: 10.2122/gbc.2006.0043


Antharacyclin-based chemotherapy benefits breast cancer patients with HER2 amplified or overexpressed tumours: new trial adds on evidence towards individualized therapy.
Evangelos Briasoulis, Dimosthenis Ziogas, Michael Fatouros, Dimitrios H. Roukos and Angelos M. Kappas
Since this article has no abstract we provide the first paragraph.

Human epidermal growth factor receptor 2 (HER2 or erbB2) is an established molecular marker of prognosis and responsiveness to breast cancer therapy. Randomized evidence suggests that breast cancer patients with HER2 amplified or overexpressed can benefit from trastuzumab therapy [1-5]


Find Delta Dental, MetLife Dental, Aetna Dentist, New York Dentist, San Francisco Dentist, Boston Dentist, Chicago Dentist, Los Angeles Dentist & San Diego Dentist at

Online ISSN : 1109 - 7647
   Print ISSN : 1109 - 7655

We subscribe to the HONcode principles of the HON Foundation. Click to verify. We subscribe to the HONcode principles. Verify here.
please, read our policy about privacy and confidentiality of information and transparency of sponsorship

last update: 3 February 2004